Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
Launched by MASSACHUSETTS GENERAL HOSPITAL · Jun 1, 2016
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how eating fewer calories might help lower the chances of complications after surgery for patients with certain types of tumors called soft tissue sarcomas, particularly those located in the lower legs. The goal is to see if reducing calorie intake before surgery, while the patient is receiving radiation therapy, can help improve healing and reduce issues like infections or delayed recovery after the operation.
To participate in this study, you need to be at least 18 years old and have been diagnosed with a soft tissue sarcoma in your lower extremities. You should be scheduled to receive radiation therapy followed by surgery to remove the tumor. Other requirements include having a good overall health status, measured by a score called the Karnofsky Score, and a normal body weight. However, this study is not for everyone; for instance, if you are pregnant, have diabetes, or have been diagnosed with another cancer recently, you may not be eligible. If you decide to join the trial, you can expect to follow a specific diet plan that limits calories as part of your treatment process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • Biopsy proven soft tissue sarcoma located in the lower extremities
- • Patient to be treated with radiation therapy for a primary lower extremity soft tissue sarcoma or recurrent tumor after surgery, followed by surgical resection
- • Karnofsky Score ≥ 60%
- • Body Mass Index (BMI) ≥ 20 kg/m2
- • Protein levels within normal limits within 45 days of enrollment
- • Normal kidney and liver function within 45 days of enrollment
- • Normal blood counts within 45 days of enrollment
- • Normal chemistries within 45 days of enrollment
- Exclusion Criteria:
- • Current pregnancy and breast feeding
- • Other cancers diagnosed within the last 5 years (in situ and/or invasive)
- • Diabetes mellitus
- • Current metformin therapy
- • Other conditions may exclude participants from the study (e.g. intractable nausea/emesis, allergic reaction to shake, patient decides not to have surgery, any medical condition that prevents patient from having surgery)
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Santiago A Lozano-Calderón, MD, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials